Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Drug repositioning candidates identified using in-silico quasi-quantum molecular simulation demonstrate reduced COVID-19 mortality in 1.5M patient records

Joy Alamgir, Masanao Yajima, Rosa Ergas, Xinci Chen, Nicholas Hill, Naved Munir, Mohsan Saeed, Ken Gersing, Melissa Haendel, Christopher G Chute, M. Ruhul Abid
doi: https://doi.org/10.1101/2021.03.22.21254110
Joy Alamgir
1ARIScience
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: joy@ariscience.com
Masanao Yajima
2Boston University, Department of Mathematics and Statistics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Ergas
1ARIScience
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinci Chen
1ARIScience
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Hill
3Great Plains Tribal Leader’s Health Board
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naved Munir
4Caromont Regional Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohsan Saeed
5Boston University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Gersing
6National Institutes of Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa Haendel
7Oregon Health & Science University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher G Chute
8Johns Hopkins University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Ruhul Abid
9Brown University,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Drug repositioning is a key component of COVID-19 pandemic response, through identification of existing drugs that can effectively disrupt COVID-19 disease processes, contributing valuable insights into disease pathways. Traditional non in silico drug repositioning approaches take substantial time and cost to discover effect and, crucially, to validate repositioned effects.

Methods Using a novel in-silico quasi-quantum molecular simulation platform that analyzes energies and electron densities of both target proteins and candidate interruption compounds on High Performance Computing (HPC), we identified a list of FDA-approved compounds with potential to interrupt specific SARS-CoV-2 proteins. Subsequently we used 1.5M patient records from the National COVID Cohort Collaborative to create matched cohorts to refine our in-silico hits to those candidates that show statistically significant clinical effect.

Results We identified four drugs, Metformin, Triamcinolone, Amoxicillin and Hydrochlorothiazide, that were associated with reduced mortality by 27%, 26%, 26%, and 23%, respectively, in COVID-19 patients.

Conclusions Together, these findings provide support to our hypothesis that in-silico simulation of active compounds against SARS-CoV-2 proteins followed by statistical analysis of electronic health data results in effective therapeutics identification.

Competing Interest Statement

Joy Alamgir is founder of ARIScience. Melissa Haendel is a co-founder of Pryzm Health.

Funding Statement

The statistical analyses we performed were conducted with data or tools accessed through the NCATS N3C Data Enclave and supported by NCATS U24 TR002306. ARIScience funded this project.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This Data Utilization request of this project (RP-392493) was approved by National Institute of Health (NIH) National COVID Cohort Collaborative (N3C) DUR Approval Committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ruhul_abid{at}brown.edu

Data Availability

National Institute of Health (NIH) National COVID Cohort Collaborative (N3C) has clear procedures for researchers to gain access to the de-identified patient data (1000+ researchers already have access to the data)

https://www.ariscience.org/p1_sc2_paper_01.html

https://ncats.nih.gov/n3c

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 06, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Drug repositioning candidates identified using in-silico quasi-quantum molecular simulation demonstrate reduced COVID-19 mortality in 1.5M patient records
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Drug repositioning candidates identified using in-silico quasi-quantum molecular simulation demonstrate reduced COVID-19 mortality in 1.5M patient records
Joy Alamgir, Masanao Yajima, Rosa Ergas, Xinci Chen, Nicholas Hill, Naved Munir, Mohsan Saeed, Ken Gersing, Melissa Haendel, Christopher G Chute, M. Ruhul Abid
medRxiv 2021.03.22.21254110; doi: https://doi.org/10.1101/2021.03.22.21254110
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Drug repositioning candidates identified using in-silico quasi-quantum molecular simulation demonstrate reduced COVID-19 mortality in 1.5M patient records
Joy Alamgir, Masanao Yajima, Rosa Ergas, Xinci Chen, Nicholas Hill, Naved Munir, Mohsan Saeed, Ken Gersing, Melissa Haendel, Christopher G Chute, M. Ruhul Abid
medRxiv 2021.03.22.21254110; doi: https://doi.org/10.1101/2021.03.22.21254110

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (194)
  • Anesthesia (54)
  • Cardiovascular Medicine (488)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5661)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (856)
  • Geriatric Medicine (88)
  • Health Economics (229)
  • Health Informatics (759)
  • Health Policy (388)
  • Health Systems and Quality Improvement (250)
  • Hematology (105)
  • HIV/AIDS (181)
  • Infectious Diseases (except HIV/AIDS) (6455)
  • Intensive Care and Critical Care Medicine (388)
  • Medical Education (116)
  • Medical Ethics (28)
  • Nephrology (90)
  • Neurology (845)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (161)
  • Occupational and Environmental Health (258)
  • Oncology (514)
  • Ophthalmology (162)
  • Orthopedics (44)
  • Otolaryngology (105)
  • Pain Medicine (47)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (248)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (113)
  • Psychiatry and Clinical Psychology (959)
  • Public and Global Health (2222)
  • Radiology and Imaging (375)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (311)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)